Cell killing by antibody–drug conjugates-Reference-Cited by-同舟云学术

Cell killing by antibody–drug conjugates

Published:2007-10 Issue:2 Volume:255 Page:232-240
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Kovtun Yelena V.,Goldmacher Victor S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference72 articles.

1. Drug-conjugated monoclonal antibodies for the treatment of cancer;Lambert;Curr. Opin. Pharmacol.,2005

2. Arming antibodies: prospects and challenges for immunoconjugates;Wu;Nat. Biotechnol.,2005

3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia;Bross;Clin. Cancer Res.,2001

4. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines;Naito;Leukemia,2000

5. Microtubules as a target for anticancer drugs;Jordan;Nat. Rev. Cancer,2004

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

2. Beyond Cytotoxic Potency: Disposition Features Required to Design ADC Payload;Xenobiotica;2024-07-17

3. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

4. Principles of Antibody Drug Development;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

5. Preparation of trastuzumab-DM1 conjugate with a high drug-to-antibody ratio for breast cancer therapy;Nano Today;2024-02